ImmunityBio, Inc. (NASDAQ:IBRX)
| Market Cap | 10.13B+287.2% |
| Revenue (ttm) | 165.79M+192.9% |
| Net Income | -992.36M-170.3% |
| EPS | -0.97-110.1% |
| Shares Out | 1.05B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,969,830 |
| Open | 9.48 |
| Previous Close | 9.69 |
| Day's Range | 9.33 - 9.93 |
| 52-Week Range | 1.95 - 12.43 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | 12.00(+24.10%) |
| Earnings Date | Nov 3, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About IBRX
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IBRX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IBRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IBRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IBRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
IBRX Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Product revenue, net | $50.67M | 98.89% |
| Other revenues | $568.00K | 1.11% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New IBRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IBRX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IBRX
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $118.76M |
| IWMiShares Russell 2000 ETF | $97.62M |
| VTIVanguard Morningstar Total Stock Market ETF | $92.41M |
| VBVanguard Morningstar Small-Cap ETF | $67.01M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $38.38M |
| IWOiShares Russell 2000 Growth ETF | $35.08M |
Estimated from each fund’s disclosed top holdings × AUM
IBRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IBRX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score